Literature DB >> 25306891

Predictive value of serum apolipoprotein B/apolipoprotein A-I ratio in metabolic syndrome risk: a Chinese cohort study.

Yu-Ching Chou1, Jen-Chun Kuan, Chyi-Huey Bai, Tsan Yang, Wan-Yun Chou, Po-Chien Hsieh, San-Lin You, Lee-Ching Hwang, Chien-Hua Chen, Cheng-Yu Wei, Chien-An Sun.   

Abstract

The purpose of this study was to evaluate whether the apolipoprotein B/apolipoprotein A-I (apoB/apoA-I) ratio is a promising risk predictor of metabolic syndrome (MetS) and to determine the optimal cut-off value of this ratio in detecting subjects with MetS in a Chinese population. A prospective study was conducted using a representative sample of non-institutionized people in Taiwan. A total of 3,343 participants with mean age (±SD) of 39.86 (±15.61) years old were followed up from 2002 to 2007. The primary outcome was the incidence of MetS. The MetS was defined according to a unified criterion established by several major organizations. There were 462 cases of incident MetS during a mean follow-up period of 5.26 years. A significantly stepwise increase in the incidence of MetS across quartiles of the apoB/apoA-I ratio was noted in both sexes after adjustment for potential confounders (p for trend <0.001). Compared with the lowest quartile of apoB/apoA-I ratio, participants in the highest quartile had a significantly higher risk of MetS in both men [adjusted hazard ratio (HR) = 6.29, 95 % confidence interval (CI) = 2.79-9.13] and women (adjusted HR = 3.82, 95 % CI = 1.06-6.63). Comparisons of receiver operating characteristics curves indicated that the predictive ability of apoB/apoA-I ratio to detect MetS was better than conventional lipid ratio measurements. Furthermore, the optimal cut-off value of apoB/apoA-I ratio for MetS diagnosis was 0.71 in men and 0.56 in women. These results suggest that an elevated apoB/apoA-I ratio might constitute a potentially crucial measure linked to the risk of developing MetS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25306891     DOI: 10.1007/s12020-014-0447-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  47 in total

1.  Ethnic-specific criteria for the metabolic syndrome: evidence from China.

Authors:  Jing Liu; Scott M Grundy; Wei Wang; Sidney C Smith; Gloria Lena Vega; Zhaosu Wu; Zhechun Zeng; Wenhua Wang; Dong Zhao
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

2.  Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

Authors:  M-R Taskinen; P J Barter; C Ehnholm; D R Sullivan; K Mann; J Simes; J D Best; S Hamwood; A C Keech
Journal:  Diabetologia       Date:  2010-06-06       Impact factor: 10.122

3.  The value of apolipoprotein B/A1 ratio in the diagnosis of metabolic syndrome in a Korean population.

Authors:  Chang Hee Jung; Jenie Yoonoo Hwang; Ji Hee Yu; Mi Seon Shin; Sung Jin Bae; Joong-Yeol Park; Hong-Kyu Kim; Woo Je Lee
Journal:  Clin Endocrinol (Oxf)       Date:  2012-11       Impact factor: 3.478

4.  The ApoB/ApoA1 ratio is associated with metabolic syndrome and its components in a Chinese population.

Authors:  Li Zhong; Qifu Li; Yuanjuan Jiang; Dan Cheng; Zhoujun Liu; Bangqiong Wang; Rong Luo; Qingfeng Cheng; Hua Qing
Journal:  Inflammation       Date:  2010-12       Impact factor: 4.092

5.  High levels of apolipoprotein B/AI ratio are associated with intracranial atherosclerotic stenosis.

Authors:  Jong-Ho Park; Keun-Sik Hong; Eun-Ja Lee; Juneyoung Lee; Dong-Eog Kim
Journal:  Stroke       Date:  2011-08-25       Impact factor: 7.914

Review 6.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 7.  CVD risk factors and ethnicity--a homogeneous relationship?

Authors:  Nita G Forouhi; Naveed Sattar
Journal:  Atheroscler Suppl       Date:  2006-02-24       Impact factor: 3.235

8.  Risk stratification of apolipoprotein B, apolipoprotein A1, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study.

Authors:  Christos Pitsavos; Demosthenes B Panagiotakos; John Skoumas; Labros Papadimitriou; Christodoulos Stefanadis
Journal:  Angiology       Date:  2008-04-02       Impact factor: 3.619

9.  International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material.

Authors:  S M Marcovina; J J Albers; H Kennedy; J V Mei; L O Henderson; W H Hannon
Journal:  Clin Chem       Date:  1994-04       Impact factor: 8.327

10.  Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices.

Authors:  John H Contois; Joseph P McConnell; Amar A Sethi; Gyorgy Csako; Sridevi Devaraj; Daniel M Hoefner; G Russell Warnick
Journal:  Clin Chem       Date:  2009-01-23       Impact factor: 8.327

View more
  3 in total

1.  The association between the apolipoprotein B/A-I ratio and coronary calcification may differ depending on kidney function in a healthy population.

Authors:  Seok-Hyung Kim; Donghwan Oh; Kwon Soo Jung; Jung Eun Lee; Hyunwook Kim; Hyung Jong Kim; Beom Seok Kim; Hyeong Cheon Park; Byoung Kwon Lee; Hoon Young Choi
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

2.  Apolipoprotein B/A1 Ratio as a Diagnostic Alternative to Triglycerides and HDL-Cholesterol for the Prediction of Metabolic Syndrome among Hypertensives in Kazakhstan.

Authors:  Alma Nurtazina; Dana Kozhakhmetova; Daulet Dautov; Aizhan Shakhanova; Vijay Kumar Chattu
Journal:  Diagnostics (Basel)       Date:  2020-07-23

3.  The Apolipoprotein B/A1 Ratio is Associated With Metabolic Syndrome Components, Insulin Resistance, Androgen Hormones, and Liver Enzymes in Women With Polycystic Ovary Syndrome.

Authors:  Hui He; Jiaxing Feng; Shike Zhang; Yu Wang; Jian Li; Jingshu Gao; Jing Cong; Yi Gong; Xiaoke Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-05       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.